<DOC>
	<DOCNO>NCT01295060</DOCNO>
	<brief_summary>This long term study evaluate safety , tolerability efficacy Octreotide Implant patient previously treat Octreotide implant .</brief_summary>
	<brief_title>Long-term Safety Efficacy Study Octreotide Implant Patients With Acromegaly</brief_title>
	<detailed_description>Evaluation long-term safety tolerability , include local tolerability implant site , 84-mg octreotide hydrogel implant subject acromegaly successfully treat 84-mg octreotide hydrogel implant Phase III study IP107-001 .</detailed_description>
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Currently enrol Extension Phase Study IP107001 receive least one 84mg octreotide hydrogel implant prior enrollment OR previously enrol Extension Phase Study IP107001 currently take lanreotide octreotide . Subjects successfully treat 84mg octreotide hydrogel implant Study IP107 001 . In opinion Investigator ; subject unstable chronic medical condition clinically significant finding would preclude subject 's participation study . Subjects must able communicate , provide sign write informed consent , willing participate comply study requirement . Pituitary surgery le 3 month prior enrollment study Liver disease ( eg , cirrhosis , chronic active persistent hepatitis persistent abnormality ALT , AST [ level &gt; 2× normal ] direct bilirubin [ level &gt; 1.5× normal ] ) Unstable angina , sustain ventricular arrhythmia heart failure ( NYHA III IV ) Acute myocardial infarction within 3 month Screening Uncontrolled diabetes define HbA1c ≥9 % Symptomatic cholelithiasis History drug alcohol abuse Received investigational drug participate another clinical trial except study IP107 001 within 30 day enrollment study Received radiotherapy pituitary tumor radiotherapy neck time prior enrollment study Receiving pegvisomant , dopamine agonist therapy combination somatostatin control GH IGF1 level prior enrollment study History presence significant cardiovascular , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease , severe coexisting , terminal systemic disease limit life expectancy , may interfere conduct study , subject incarcerate penal institution commit mental institution Women pregnant lactating . For female childbearing potential , positive pregnancy test prior enrollment , unwillingness use accept form reliable birth control study duration ( include bilateral tubal ligation , use oral contraceptive , double barrier method [ diaphragm spermicidal gel condom contraceptive foam ] , DepoProvera® , hormonal implant , partner vasectomy , total abstinence ) . Pregnancy test require ( indicate `` n/a '' ) male , female childbearing potential ( postmenopausal last menstrual period &gt; 1 year ago total hysterectomy bilateral oophorectomy ) An unwillingness part male subject abstain sexual intercourse pregnant lactate woman unwillingness use condom spermicide another form contraception ( eg , IUD , birth control pills take female partner , diaphragm spermicide ) engage sexual intercourse woman could become pregnant discharge study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Acromegaly</keyword>
	<keyword>Octreotide</keyword>
	<keyword>IGF-1</keyword>
	<keyword>Growth Hormone</keyword>
	<keyword>Implant</keyword>
	<keyword>Hydrogel</keyword>
</DOC>